Literature DB >> 6121522

Renal and biliary elimination of vecuronium (ORG NC 45) and pancuronium in rats.

R A Upton, T L Nguyen, R D Miller, N Castagnoli.   

Abstract

The urinary excretion of ORG NC 45 (Vecuronium) and of pancuronium was studied in unanesthetized rats and the biliary excretion was studied in anesthetized rats. Urine and bile were analyzed for unchanged drug by a new and specific mass spectrometric assay. Pancuronium was eliminated primarily in the urine (85% +/- 6% of the dose in 12 hours), but little ORG NC 45 appeared in the urine (3.5% +/- 1.1% in 12 hours). Biliary excretion accounted for 46% +/- 4% of the ORG NC 45 dose in 7 hours, but only 7.5% +/- 5.3% of an injected dose of pancuronium appeared in the bile. Thus, it appears that ORG NC 45 (a monoquaternary ammonium compound) has a higher biliary clearance than pancuronium (a bisquaternary ammonium compound). The different biodisposition of these two compounds may be due to the greater lipophilicity and concomitant enhanced permeability into the hepatocyte of ORG NC 45. We conclude that in the rat elimination of pancuronium is primarily via the kidney whereas elimination of ORG NC 45 is dependent on nonrenal mechanisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121522

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  13 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 2.  Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations.

Authors:  D K Meijer; W E Mol; M Müller; G Kurz
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

3.  Oral clonidine does not alter vecuronium neuromuscular blockade in anaesthetized patients.

Authors:  H Takahashi; T Nishikawa
Journal:  Can J Anaesth       Date:  1995-06       Impact factor: 5.063

4.  Vecuronium neuromuscular block in patients with malignant obstructive jaundice.

Authors:  A Baraka
Journal:  Can J Anaesth       Date:  1994-08       Impact factor: 5.063

Review 5.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  Secondary hyperparathyroidism shortens the action of vecuronium in patients with chronic renal failure.

Authors:  K Takita; Y Goda; O Kemmotsu; H Mashio; A Okuyama; Y Ito; H Sakamoto; H Kawahigashi
Journal:  Can J Anaesth       Date:  1995-05       Impact factor: 5.063

7.  Pharmacokinetics and pharmacodynamics of vecuronium bromide.

Authors:  T Nomura
Journal:  J Anesth       Date:  1992-01       Impact factor: 2.078

8.  Vecuronium in renal failure.

Authors:  D R Bevan; F Donati; H Gyasi; A Williams
Journal:  Can Anaesth Soc J       Date:  1984-09

Review 9.  New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use.

Authors:  C S Reilly; W S Nimmo
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

10.  Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.

Authors:  A Sidi; R F Kaplan; R F Davis
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.